Staphylococcus aureus wall teichoic acid bearing β-N-acetylglucosamine glycosylation (β-GlcNAc-WTA)

Staphylococcus aureus wall teichoic acid (WTA) bearing β-N-acetylglucosamine (β-GlcNAc) glycosylation is a major surface glycopolymer and a critical determinant of bacterial virulence and antibiotic resistance. In S. aureus, WTA typically consists of a ribitol phosphate polymer that is post-translationally modified by the glycosyltransferase TarS, which attaches GlcNAc in a β-linkage to the C4 position of the ribitol units (PMID: 22493231). This specific modification is essential for the expression of methicillin resistance in MRSA strains, as it facilitates the proper localization and function of PBP2a, and it serves as the primary receptor for many S. aureus-specific bacteriophages (PMID: 23435302, PMID: 26151323). As a therapeutic target, β-GlcNAc-WTA is highly attractive because it is abundantly displayed on the bacterial surface and is relatively conserved across clinical S. aureus isolates. It is the specific epitope recognized by the monoclonal antibody component of DSTA3837S (RG7861), an antibody-antibiotic conjugate designed to deliver a potent dimethyl-rifampicin derivative directly to the bacterium, which is then internalized and released within host macrophages to kill intracellular S. aureus (PMID: 26536114). While S. aureus can also produce α-GlcNAc-WTA via the TarM enzyme, the β-glycosylated form is more closely associated with the MRSA phenotype and immune system interactions, making it a focal point for novel antibacterial strategies including vaccines and passive immunotherapies (PMID: 29891864).

Other names

β-GlcNAc-WTAβ-glycosylated wall teichoic acidTarS-modified wall teichoic acidStaphylococcus aureus β-O-GlcNAc wall teichoic acid

Targeting by monoclonal antibodies to facilitate opsonophagocytic killing or to deliver intracellular antibiotics via antibody-antibiotic conjugates (AACs).